Prospects and therapeutic strategies in the management of dry eye disease: a review
- 30 June 2026
- journal article
- review article
- Published by ECO-Vector LLC (Publications) in Ophthalmology Reports
- Vol. 19 (2) , 83-93
Abstract
Dry eye disease (DED) is a widespread multifactorial disease, which makes the search for new effective therapies highly relevant. The novelty of this review lies in the comprehensive examination of the pathogenesis of DED and the substantiation of a promising treatment direction using corneal extracellular matrix biomimetics. The analysis showed that modern therapy of DED is not limited to simple lubrication and should be aimed at restoring ocular surface homeostasis and breaking the vicious cycle of chronic inflammation. Furthermore, it was found that multi-component preparations based on extracellular matrix biomimetics, in particular SFERO® Oko (BIOMIR Service JSC, Russia), demonstrate high efficacy in stimulating corneal regeneration and are promising for inclusion in therapeutic regimens for dry eye disease. Special attention is paid to drugs approved by the U.S. Food and Drug Administration, including cyclosporine; Xiidra® (lifitegrast 5%, Bausch Lomb Inc., USA)[℘]; Eysuvis® (loteprednol etabonate 0.25%, Kala Pharmaceuticals, USA)[℘]; Miebo® (perfluorohexyloctane, Novaliq, Germany)[℘]; and Tyrvaya® (varenicline nasal spray, Oyster Point Pharma Inc., USA)[℘]. This scientific review is based on an analysis of Russian and international sources from 2015 to 2025 and is intended for practicing ophthalmologists seeking a personalized approach to dry eye disease treatment. [℘] A drug is not registered in the Russian Federation.Keywords
This publication has 51 references indexed in Scilit:
- Genomics of Staphylococcus aureus and Enterococcus faecalis isolated from the ocular surface of dry eye disease sufferersExperimental Eye Research, 2024
- Quintessence of currently approved and upcoming treatments for dry eye diseaseGraefe's Archive for Clinical and Experimental Ophthalmology, 2024
- Investigation of lacrimal gland and extraocular muscle in thyroid eye disease patients with severe subjective dry eye disease: a multiparametric magnetic resonance imaging studyGraefe's Archive for Clinical and Experimental Ophthalmology, 2024
- Ocular microbiome changes in dry eye disease and meibomian gland dysfunctionExperimental Eye Research, 2023
- Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye DiseaseOphthalmology, 2022
- Tear lipid supplement prophylaxis against dry eye in adverse environmentsContact Lens and Anterior Eye, 2018
- A Two-Week, Randomized, Double-masked Study to Evaluate Safety and Efficacy of Lubricin (150 μg/mL) Eye Drops Versus Sodium Hyaluronate (HA) 0.18% Eye Drops (Vismed®) in Patients with Moderate Dry Eye DiseaseThe Ocular Surface, 2017
- The chondrogenic differentiation of mesenchymal stem cells on an extracellular matrix scaffold derived from porcine chondrocytesBiomaterials, 2010
- A Comparison of Vitamin A and Cyclosporine A 0.05% Eye Drops for Treatment of Dry Eye SyndromeAmerican Journal of Ophthalmology, 2009
- Oxidative reactions in the tear fluid of patients suffering from dry eyesGraefe's Archive for Clinical and Experimental Ophthalmology, 1995